2-(5-Methyl-3-pyridyl)-2-propanol | 40472-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(5-Methyl-3-pyridyl)-2-propanol
• 英文别名: 2-(5-methyl-pyridin-3-yl)-propan-2-ol；2-(5-Methylpyridin-3-yl)propan-2-ol
• CAS: 40472-86-4
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: FNTVYXVBLVGJIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS D'OXAZOLE UTILES COMME INHIBITEURS DE FAAH
  申请人：MERCK & CO INC

  公开号：WO2010017079A1

  公开（公告）日：2010-02-11

  The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些噁唑衍生物，其可用作脂肪酸酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20140038936A1

  公开（公告）日：2014-02-06

  The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及用作PI3K抑制剂的化合物，特别是PI3Kγ的抑制剂。本发明还提供了包含该化合物的药学上可接受的组合物，并提供了使用该组合物治疗各种疾病、病况或障碍的方法。
• OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140171437A1

  公开（公告）日：2014-06-19

  The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些噁唑衍生物，其可用作脂肪酸酰胺水解酶（FAAH）的抑制剂。本发明还涉及含有这些化合物作为活性成分的制药组合物以及这些化合物及其制剂在治疗某些疾病，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌疼痛和纤维肌痛以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病中的应用。
• NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
  申请人：Boga Sobhana Babu

  公开号：US20130237518A1

  公开（公告）日：2013-09-12

  Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1).

  本发明公开了式（1）的ERK抑制剂及其药学上可接受的盐，其中：A是五元杂环单环芳基环；B是单环杂环烷基环，或单环杂环烯基环，或桥接的单环杂环烷基环，或融合的（单环杂环烷基环）环丙基环。本发明还公开了使用式（1）的化合物治疗癌症的方法。
• [EN] SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE D'AMINOBENZYLE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS D'EGFR ET/OU DE PI3K
  申请人：MEKANISTIC THERAPEUTICS LLC

  公开号：WO2022140456A1

  公开（公告）日：2022-06-30

  This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I, or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof, wherein the variables Ring A, X, R1a, R1b, R2, R3, R4, m, n, and p are described herein, which function as dual inhibitors of EGFR proteins and PI3K proteins. The disclosure further relates to the use of the compounds described herein as therapeutics for the treatment of diseases and conditions mediated by EGFR proteins and/or PI3K proteins, such as cancer and other diseases.

  本公开涉及药物化学领域，涉及一类新的小分子化合物，其具有式I，或其药学上可接受的盐或溶剂化物，或其对映体，对映体混合物，两个或两个以上的非对映异构体混合物，或其同位素变体，其中变量环A、X、R1a、R1b、R2、R3、R4、m、n和p在本文中有所描述，其作为EGFR蛋白和PI3K蛋白的双重抑制剂。本公开进一步涉及将所述化合物用作治疗EGFR蛋白和/或PI3K蛋白介导的疾病和病状的治疗剂，例如癌症和其他疾病。